neurodegenerative disease

Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.

Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.

New research suggests that some risky and protective variants in the LRRK2 gene have shared genetic effects in Crohn's disease and Parkinson's disease.

The Boston-based hospitals will provide Berg access to clinically annotated patient-derived specimens to track neurological disease pathology and develop diagnostic tools.

The Martinos Center, Envision Genomics, and startup RowAnalytics are building an open precision medicine platform called Giro Health on IBM architecture.

ImmunArray will use Quanterix's Simoa single-molecule array technology for biomarker analysis, with the potential to enrich its diagnostic panels.

The funding will support development of tests that detect cell-free DNA methylation patterns indicative of disease in specific tissues of the body.

The RNA products developer is buying California-based Narus in order to expand into the RNA-based diagnostics market.

The companies will evaluate Diamir's technology as a potential companion diagnostic to certain Janssen neurodegenerative disease programs.

UK-based XRGenomics is using Affymetrix's GeneTitan platform to develop a gene expression signature as a stratification tool for dementia research.

Pages

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.